Hormone Receptor-positive Breast Cancer
📧 Sign up to get email alerts when something new happens for Hormone Receptor-positive Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-06-29Clinical Trial Update: A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
This ClinicalTrials.gov update reports results from a completed Danish study of HR+/HER2- metastatic breast cancer patients treated with pal…
-
CLINICAL_TRIALS trial_result · 2025-05-31Clinical Trial Update: Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer [Phase 1]
A Phase 1 trial evaluating ribociclib in combination with PDR001 for metastatic hormone-receptor-positive (HR+) breast cancer, HER2-negative…
-
CLINICAL_TRIALS trial_result · 2025-05-04Clinical Trial Update: Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy [Phase 2]
Phase 2 clinical trial assessing albumin-bound sirolimus in combination with endocrine therapy for HR+/HER2- advanced/metastatic breast canc…
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: PRE-I-SPY Phase I/Ib Oncology Platform Program [Phase 1]
Pre-I-SPY Phase I/Ib oncology platform program update with Phase 1 recruitment ongoing across multiple breast cancer indications, including …
-
CLINICAL_TRIALS trial_result · 2025-02-27Clinical Trial Update: Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer [Phase 2]
Phase 2 clinical trial update evaluating correlation between clinical response and pathologic response in patients with early breast cancer.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-02-06Clinical Trial Update: WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor [Phase 1]
A Phase 1 study evaluating the three-drug combination bosutinib, palbociclib, and fulvestrant for HR-positive, HER2-negative metastatic brea…
-
CLINICAL_TRIALS trial_result · 2024-12-20Clinical Trial Update: Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating SHR-A1921 in combination with Adebrelimab for advanced hormone-receptor-positive, HER2-negative breast can…
-
CLINICAL_TRIALS trial_result · 2024-11-08Clinical Trial Update: A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer [Phase 1]
This is a Phase 1 trial evaluating ipatasertib plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in hormone r…
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO [Phase 2]
Phase 2 trial comparing a CDK4/6 inhibitor with endocrine therapy to chemotherapy with endocrine therapy in advanced/metastatic breast cance…
-
CLINICAL_TRIALS trial_result · 2024-07-31Clinical Trial Update: A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer [Phase 1]
This Phase 1 dose-escalation trial of taselisib (GDC-0032) in locally advanced or metastatic solid tumors or Non-Hodgkin lymphoma, including…
-
CLINICAL_TRIALS trial_result · 2024-07-30Clinical Trial Update: Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer [Phase 1]
Phase 1 study evaluating the addition of copanlisib to fulvestrant and abemaciclib for metastatic breast cancer, with results posted in 2024…
-
CLINICAL_TRIALS trial_result · 2024-07-29Clinical Trial Update: Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer [Phase 2]
A Phase 2 trial evaluating palbociclib in combination with tamoxifen as first-line therapy for metastatic hormone receptor-positive, HER2-ne…
-
CLINICAL_TRIALS trial_result · 2024-04-23Clinical Trial Update: Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients [Phase 2]
Phase 2 trial update evaluating a higher dose of preoperative taMOxifen in premenopausal women with hormone receptor-positive breast cancer.
-
CLINICAL_TRIALS trial_result · 2024-04-05Clinical Trial Update: Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer [Phase 2]
A Phase 2 trial evaluated two ribociclib dose levels in combination with aromatase inhibitors for HR-positive, HER2-negative advanced breast…
-
CLINICAL_TRIALS trial_result · 2023-12-12Clinical Trial Update: Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant [Phase 2]
Phase 2 trial evaluating safety and efficacy of adding dapagliflozin to extended-release metformin versus metformin XR alone in HR+, HER2-, …
-
CLINICAL_TRIALS trial_result · 2023-06-15Clinical Trial Update: TCb vs EC-T in High Risk ER+/HER2- Breast Cancer [Phase 3]
Phase 3 clinical trial update comparing TCb versus EC-T in high-risk ER+/HER2- breast cancer; currently recruiting.
-
CLINICAL_TRIALS trial_result · 2023-06-12Clinical Trial Update: Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer [Phase 3]
Phase 3 trial evaluating docetaxel, carboplatin, trastuzumab, and pertuzumab with or without estrogen deprivation in hormone receptor-positi…
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients [Phase 4]
Phase 4 clinical trial updating on ribociclib efficacy and resistance patterns in advanced breast cancer.
-
CLINICAL_TRIALS trial_result · 2022-08-29Clinical Trial Update: Palbociclib With Everolimus + Exemestane In BC [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating palbociclib in combination with everolimus and exemestane in HER2-negative, HR-positive breast cancer …
-
CLINICAL_TRIALS trial_result · 2021-11-16Clinical Trial Update: Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic [Phase 3]
Phase 3 trial evaluating exemestane with or without entinostat in recurrent hormone receptor-positive, HER2-negative breast cancer that is l…
-
CLINICAL_TRIALS trial_result · 2020-07-07Clinical Trial Update: Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors [Phase 2]
A Phase 2 clinical trial evaluating neoadjuvant response-guided treatment for slowly proliferating hormone receptor positive breast tumors.
-
CLINICAL_TRIALS trial_result · 2019-04-10Clinical Trial Update: Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC [Phase 2]
A Phase 2 trial evaluating pyrotinib in combination with trastuzumab and AI for first-line treatment of HER2-positive, hormone receptor-posi…
-
CLINICAL_TRIALS trial_result · 2018-09-10Clinical Trial Update: Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer [Phase 2]
Phase 2 trial comparing neoadjuvant letrozole plus metformin versus letrozole plus placebo in ER-positive postmenopausal breast cancer compl…
-
CLINICAL_TRIALS trial_result · 2017-11-13Clinical Trial Update: Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab [Phase 4]
Phase 4 trial update describes patient preferences for combining everolimus with exemestane or capecitabine with bevacizumab in recurrent HE…
-
CLINICAL_TRIALS trial_result · 2017-04-11Clinical Trial Update: Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer [Phase 2]
Phase 2 trial update for an investigational vaccine therapy in stage IV hormone receptor-positive breast cancer has been terminated.